nice_new_london_office_internal_3_web

NICE shoots down Dupixent for severe asthma

pharmafile | March 9, 2020 | News story | Sales and Marketing |  Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma 

NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 inhibitor Dupixent (dupilumab) in the treatment of severe asthma.

The indication specifically relates to patients with type 2 inflammation that does not respond adequately to the combination of high-dose inhaled corticosteroids and another maintenance therapy.

The decision was made despite data indicating the superiority of Dupixent, when combined with standard asthma treatment, compared to placebo in reducing exacerbation frequency and reliance on oral corticosteroids in this patient population.

Ultimately, this was due to cost estimates for use of the drug coming in at a level higher than NHS resources would support.

Advertisement

Patients in this target population often prove difficult to treat and are prone to hospitalisation when sudden exacerbations arise.

Matt Fellows

Related Content

“That gap between innovation and delivery was what stood out to me most”

Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and …

Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study

People in their forties account for almost three-quarters of those who do not attend NHS …

Excellence in Healthcare Partnership Awards – A Collaborative Working Project Between Sanofi and The University Hospital Birmingham Severe Asthma Team

Launched in February 2026 by PMGroup Worldwide Ltd and Visions4Health, the Excellence in Healthcare Partnerships …

The Gateway to Local Adoption Series

Latest content